Skip to main content
    F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.71
    -0.06 (-1.59%)

    Market Cap: $287.96M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fulcrum Therapeutics Inc (FULC) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Fulcrum Therapeutics (FULC) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Fulcrum Therapeutics reported EPS of -$0.11, in line with the -$0.11 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(17/29)
    Avg Surprise
    +1.53%

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.10
    Range-$0.30 - -$0.02
    8 analysts
    Revenue Consensus
    N/A
    RangeN/A
    7 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.36
    Range-$0.36 - -$0.36
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.38+4.0%
    60d ago-$0.30-18.7%
    30d ago-$0.28-30.1%
    7d ago-$0.30-20.0%
    Current-$0.36
    Revenue Consensus
    N/A
    RangeN/A
    1 analysts

    Next Report

    FULC has an expected report date of Feb 22, 2027.

    FULC Earnings Call

    The latest FULC earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, FULC beat 17, missed 11 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 36.48% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.11-$0.11-$0.13 - -$0.080.00%In lineN/A21 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$0.29-$0.21-$0.31 - -$0.04-36.48%MissN/A74 up, 0 downJul 30, 2026N/A
    Mar 31, 2026-$0.25-$0.30-$0.38 - -$0.24+16.67%BeatN/A113 up, 5 downApr 27, 2026N/A
    Dec 31, 2025-$0.31-$0.31-$0.33 - -$0.25-1.47%MissN/A112 up, 1 downFeb 24, 2026N/A
    Sep 30, 2025-$0.31-$0.29-$0.34 - -$0.26-6.90%MissN/A85 up, 1 downOct 29, 2025N/A
    Jun 30, 2025-$0.28-$0.29-$0.31 - -$0.26+3.45%Beat-132.2%81 up, 0 downJul 29, 2025N/A
    Mar 31, 2025-$0.28-$0.29N/A+3.45%BeatN/A20 up, 1 downMay 1, 2025N/A
    Dec 31, 2024-$0.31-$0.29-$0.34 - -$0.23-7.53%MissN/A64 up, 2 downFeb 25, 2025N/A
    Sep 30, 2024-$0.46-$0.40-$0.47 - -$0.37-15.00%MissN/A90 up, 0 downNov 13, 2024N/A
    Jun 30, 2024$0.87$0.06-$0.46 - $0.74N/AN/AN/A80 up, 0 downJul 31, 2024$80.00M
    Mar 31, 2024-$0.43-$0.44-$0.46 - -$0.39+2.27%BeatN/A80 up, 0 downMay 13, 2024N/A
    Dec 31, 2023-$0.40-$0.43-$0.50 - -$0.38+6.98%BeatN/A70 up, 0 downFeb 27, 2024$871000
    Sep 30, 2023-$0.39-$0.44-$0.46 - -$0.39+11.36%BeatN/A61 up, 0 downNov 7, 2023$759000
    Jun 30, 2023-$0.38-$0.44-$0.48 - -$0.39+13.64%BeatN/A70 up, 0 downAug 3, 2023$880000
    Mar 31, 2023-$0.41-$0.46-$0.55 - -$0.39+10.87%BeatN/A80 up, 0 downMay 15, 2023$295000
    Dec 31, 2022-$0.50-$0.49-$0.53 - -$0.41-2.04%MissN/A90 up, 1 downMar 9, 2023$685000
    Sep 30, 2022-$0.50-$0.61-$0.74 - -$0.47+18.03%BeatN/A81 up, 0 downNov 8, 2022$1.18M
    Jun 30, 2022-$0.83-$0.66-$0.74 - -$0.58-25.76%MissN/A80 up, 0 downAug 11, 2022$1.88M
    Mar 31, 2022-$0.64-$0.63-$0.74 - -$0.57-1.59%MissN/A80 up, 0 downMay 9, 2022$2.59M
    Dec 31, 2021-$0.58-$0.73-$1.13 - -$0.54+20.55%BeatN/A70 up, 0 downMar 3, 2022$5.06M
    Sep 30, 2021-$0.57-$0.65-$0.74 - -$0.57+12.31%BeatN/A76 up, 0 downNov 4, 2021$4.93M
    Jun 30, 2021-$0.60-$0.65-$0.69 - -$0.56+7.69%BeatN/A6N/AAug 10, 2021$4.38M
    Mar 31, 2021-$0.54-$0.66-$0.70 - -$0.62+18.18%BeatN/A6N/AMay 6, 2021$4.79M
    Dec 31, 2020-$0.64-$0.72-$0.77 - -$0.69+11.11%BeatN/A6N/AMar 4, 2021$4.22M
    Sep 30, 2020-$0.70-$0.64-$0.75 - -$0.59-9.38%MissN/A6N/ANov 10, 2020$1.85M
    Jun 30, 2020-$0.66-$0.75-$0.95 - -$0.68+12.00%BeatN/A5N/AAug 11, 2020$2.00M
    Mar 31, 2020-$0.81-$0.75-$0.82 - -$0.70-8.00%MissN/A3N/AMay 13, 2020$750000
    Dec 31, 2019-$0.71-$0.88-$1.05 - -$0.69+19.32%BeatN/A4N/AMar 5, 2020N/A
    Sep 30, 2019-$0.97-$0.72-$10.05 - -$0.42-34.72%MissN/A4N/ANov 14, 2019N/A
    Jun 30, 2019-$0.71-$0.75-$5.45 - -$0.75+5.33%BeatN/A2N/AAug 26, 2019N/A
    Mar 31, 2019-$0.31N/AN/AN/AN/AN/AN/AN/AMay 29, 2019N/A
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.18, after -$0.33 the year before. It was -$2.70 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.18N/A
    Dec 31, 2024-$0.33N/A
    Dec 31, 2023-$1.58N/A
    Dec 31, 2022-$2.47N/A
    Dec 31, 2021-$2.29N/A
    Dec 31, 2020-$2.81N/A
    Dec 31, 2019-$2.70N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,000 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20264,99311
    2025Q4Dec 31, 20257,09912
    2025Q3Sep 30, 20255,42112
    2025Q1Mar 31, 20254,1279
    2024Q4Dec 31, 20245,78710
    2024Q3Sep 30, 20245,07212
    2024Q2Jun 30, 20244,85110

    2026Q1 Earnings Call

    Opening remarks

    Alexander Sapir Chief Executive Officer & President That's great. Thanks, Shannon, and good morning, everyone. We appreciate you all joining us today. The first quarter of 2026 was an important and exciting period for Fulcrum highlighted by the positive clinical data we reported from the Phase Ib PIONEER trial of pociredir in sickle cell disease. Now as a reminder, sickle cell disease is a serious genetic blood disorder with a significant unmet need, affecting approximately 120,000 patients in the United States and millions more globally. Patients with sickle cell disease face a substantial disease burden, including chronic pain and fatigue as well as serious complications, such as vaso-occlusive crises, stroke and progressive end organ damage, all of which result in a substantial reduction in life expectancy of over 20 years. Now we have known for decades that increasing levels of fetal hemoglobin, or HbF, in patients with sickle cell disease leads to improvements in anemia and reductions in vaso-occlusive pain crises. And so it was for that reason that we were so pleased with the data that we reported in February, demonstrating that after only 12 weeks of treatment, 20 milligrams of pociredir taken once daily demonstrated a robust and clinically meaningful increase in HbF from 7.1% at baseline to 19.3% at week 12, along with improvements in markers of hemolysis and improvements in anemia. We also observed continued progression toward pancellular expression of HbF, which we believe is critical for achieving meaningful clinical benefit. And importantly, we saw a reduction in the number of VOCs we would have expected in this severe patient population with 7 of the 12 patients experiencing no VOCs during the 12-week treatment period. And importantly, pociredir has continued to be generally well tolerated with no treatment-related serious adverse events reported to date. And so taken together, these data reinforce our conviction in pociredir's potential to address the underlying biology of sickle cell disease and support our belief that pociredir has the potential to represent a differentiated, once-daily oral treatment option for patients. Now during the quarter, we also initiated an open-label, long-term dosing trial for patients in the PIONEER study, and we recently enrolled our first patient in this new study. All patients in this long-term dosing study previously completed 12 weeks of treatment as part of the PIONEER trial. Therefore, we expect this study to provide a distinct data set offering important insights into long-term safety, durability of response and the effects of reinitiating treatment with pociredir.

    Frequently Asked Questions About FULC

    When is Fulcrum Therapeutics's next earnings date?

    Fulcrum Therapeutics's next earnings report is expected for Feb 22, 2027.

    Did FULC beat earnings estimates last quarter?

    Fulcrum Therapeutics reported EPS of -$0.11 for the quarter ended Sep 30, 2026, in line with the -$0.11 estimate.

    What EPS do analysts expect from FULC next quarter?

    The consensus EPS estimate for Fulcrum Therapeutics for the quarter ending Dec 31, 2026 is -$0.10 from 8 analysts, with estimates from -$0.30 to -$0.02.

    How often does FULC beat earnings estimates?

    Fulcrum Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -3.60%.